Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACIU
#6081
AC Immune SA
2.9
3
-0.34%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-0.34%
Monthly Change
-17.93%
6 month change
+42.23%
Year Change
+14.45%
Previous Close
2.9
4
Open
2.9
3
Bid
Ask
Low
2.9
3
High
2.9
3
Volume
17
Markets
US Stock Market
Healthcare
ACIU
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
100.41 M
366.71 M
Valuation ratios
Enterprise value
271.11 M
1.33 B
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
News
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor
2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
Tesla and Rivian among market cap stock movers on Friday
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - AC Immune (NASDAQ:ACIU)
AC Immune stock rises after positive Parkinson’s disease trial data
AC Immune’s Parkinson’s treatment shows promise in slowing disease
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
AC Immune reports first TDP-43 PET tracer characterization in study
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?